US-China Biomedical Technology, Inc. (Form: 4, Received: 07/05/2019 16:14:23)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Huang Qingxi	2. Issuer Name and Ticker or Trading Symbol US-China Biomedical Technology, Inc. [ UCBB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO, CFO, Secy., Treas.
(Last) (First) (Middle) 21F, HUALING BUILDING, 111 FURONG RD, CHANGSHA	3. Date of Earliest Transaction (MM/DD/YYYY) 5/29/2019
(Street) HUNAN PROVINCE, CHINA, F4 410000	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	5/29/2019		P		4,290,000	A	$214,500	12,422,000	I	See footnote ⁽¹⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant	$0.05	5/29/2019		P		10,725,000		5/24/2019	11/24/2020	Common Stock	10,725,000	$0.05	10,725,000	I	See footnote ⁽²⁾

Explanation of Responses:
(1)	On May 29, 2019, China Israel Biotechnology Co. Ltd. ("CIB"), a Chinese corporation, of which Mr. Huang is a controlling officer and director of, acquired 4,290,000 units at purchase price of $0.05 per share. Each single Unit consists of one (1) share of common stock of the Company and two and one half (2.5) warrants (collectively the "Units"), which shall be exercisable for 18 months at $0.05 per share (the "Warrants").
(2)	Mr. Huangs beneficial ownership includes 10,922,000 shares held by CIB and 1,500,000 shares held by Central Bio-MD Valley Technology Co., Ltd. ("CBV"), a Chinese corporation. Mr. Huang is a controlling officer and director of CIB and CBV and has voting and dispositive control over the shares.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Huang Qingxi 21F, HUALING BUILDING 111 FURONG RD, CHANGSHA HUNAN PROVINCE, CHINA, F4 410000	X	X	CEO, CFO, Secy., Treas.

Signatures
/s/ Qingxi Huang		7/5/2019
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.